vs
Side-by-side financial comparison of OmniAb, Inc. (OABI) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $8.4M, roughly 1.1× OmniAb, Inc.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -169.3%, a 108.9% gap on every dollar of revenue. On growth, OmniAb, Inc. posted the faster year-over-year revenue change (-22.5% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-5.7M). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -51.3%).
OmniAb, Inc. is a global biotechnology firm specializing in proprietary transgenic animal platforms and antibody discovery solutions. It partners with pharma and biotech clients to accelerate fully human therapeutic antibody development for oncology, autoimmune diseases and high-need medical areas across key global markets.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
OABI vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.4M | $9.1M |
| Net Profit | $-14.2M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | -188.2% | -51.1% |
| Net Margin | -169.3% | -60.3% |
| Revenue YoY | -22.5% | -49.9% |
| Net Profit YoY | -8.5% | -184.8% |
| EPS (diluted) | $-0.11 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.4M | $9.1M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | — | $15.7M | ||
| Q1 25 | — | $10.1M | ||
| Q4 24 | $10.8M | $18.2M | ||
| Q3 24 | — | $18.0M | ||
| Q2 24 | $7.6M | $13.5M | ||
| Q4 23 | $4.8M | $10.5M |
| Q4 25 | $-14.2M | $-5.5M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $164.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | $-13.1M | $6.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | $-13.6M | $-2.2M | ||
| Q4 23 | $-14.1M | $-6.0M |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q4 23 | — | 15.5% |
| Q4 25 | -188.2% | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | -147.0% | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | -214.1% | -18.0% | ||
| Q4 23 | -439.8% | -53.5% |
| Q4 25 | -169.3% | -60.3% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | -35.8% | ||
| Q4 24 | -121.0% | 35.6% | ||
| Q3 24 | — | 18.0% | ||
| Q2 24 | -179.0% | -16.4% | ||
| Q4 23 | -291.4% | -57.6% |
| Q4 25 | $-0.11 | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | $-0.13 | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | $-0.13 | $-0.03 | ||
| Q4 23 | $-0.14 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.5M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $267.0M | $48.2M |
| Total Assets | $300.9M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.5M | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | $27.6M | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | $20.8M | $23.4M | ||
| Q4 23 | $16.4M | $23.6M |
| Q4 25 | $267.0M | $48.2M | ||
| Q3 25 | — | $52.9M | ||
| Q2 25 | — | $49.9M | ||
| Q1 25 | — | $45.2M | ||
| Q4 24 | $287.6M | $43.2M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | $294.2M | $28.6M | ||
| Q4 23 | $314.6M | $33.6M |
| Q4 25 | $300.9M | $82.3M | ||
| Q3 25 | — | $82.3M | ||
| Q2 25 | — | $78.5M | ||
| Q1 25 | — | $73.9M | ||
| Q4 24 | $325.6M | $73.4M | ||
| Q3 24 | — | $61.6M | ||
| Q2 24 | $337.3M | $91.5M | ||
| Q4 23 | $375.2M | $84.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.7M | $2.0M |
| Free Cash FlowOCF − Capex | $-5.7M | $1.6M |
| FCF MarginFCF / Revenue | -67.8% | 17.8% |
| Capex IntensityCapex / Revenue | 0.1% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-31.8M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.7M | $2.0M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | — | $-5.2M | ||
| Q1 25 | — | $-5.1M | ||
| Q4 24 | $-3.9M | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | $-12.2M | $-3.6M | ||
| Q4 23 | $-9.1M | $3.6M |
| Q4 25 | $-5.7M | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $-3.9M | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $-12.9M | $-3.8M | ||
| Q4 23 | $-9.2M | $3.3M |
| Q4 25 | -67.8% | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | -36.3% | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | -169.9% | -28.1% | ||
| Q4 23 | -191.4% | 31.9% |
| Q4 25 | 0.1% | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 0.4% | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | 9.9% | 1.3% | ||
| Q4 23 | 2.2% | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OABI
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
